Business
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, currently sold under the brand name
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"text","content":"New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, currently sold under the brand name Zofran®, was the 53rd most commonly prescribed medication in the U.S. in 2023Global ondansetron market size valued at approximately $1.4 billion in 2023 ESTERO, FL / ACCESS Newswire / February 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (\"Aspire\" or the \"Company\"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled \"A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof,\" marks the first-ever sublingual powder delivery system for ondansetron-the active ingredient in Zofran®. Aspire's formulation is designed to provide rapid relief for patients suffering from nausea and vomiting induced by chemotherapy, radiation, or surgery.Redefining Nausea Relief: IV Speed Without the NeedleOndansetron is currently limited by a roughly 30-minute delay when taken as a tablet. NIHAspire's sublingual platform is engineered to deliver:Near-Instant Absorption: Bypasses the gastrointestinal tract and first-pass metabolism, potentially reducing onset of action from 30 minutes to just minutes.Clinical Comparability: Designed to mirror the speed of intravenous (IV) administration without the need for hospital-based injections or professional assistance.Patient Compliance: Specifically addresses the \"unmet need\" for patients who cannot swallow tablets due to severe emesis (vomiting) or gastric irritation.Strategic Market PositioningSignificant and Growing Utilization: Ondansetron was the 53rd most prescribed medication in the U.S. in 2023, with over 12.5 million prescriptions, according to ClinCalc.Market Growth: The global ondansetron market is projected to grow from $1.4 billion (2023) to $2.4 billion by 2032, driven by rising cancer incidences and expanded surgical procedures, according to DATAINTELO.Accelerated Approval Path: Aspire intends to utilize the FDA's 505(b)(2) regulatory pathway, which leverages existing safety data to streamline clinical development and reduce time-to-market.CEO Commentary\"This product candidate exemplifies the real-world clinical benefits o...